GSK exits clinical oncology cell therapies with NY-ESO-1 drops

More programs fall from GSK’s struggling cancer pipeline as the pharma terminates at least three TCR cell therapy programs against NY-ESO-1 and ends its deal with Lyell. The moves take GSK out of the clinical oncology cell therapy arena completely, and serve another blow to cell therapy development for solid tumors.

Lyell Immunopharma Inc. (NASDAQ:LYEL) disclosed on Monday that GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is terminating a 2019 collaboration to develop genetically and epigenetically modified T cell therapies for cancer. It’s also discontinuing development of a pair of preclinical and an early clinical TCR T cell therapies targeting NY-ESO-1 that incorporate Lyell’s reprogramming technology...